Skip to main content
    R

    Rxsight Inc (RXST)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $4.53
    -0.13 (-2.79%)

    Market Cap: $188.00M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(15/21)
    Avg Surprise
    +16.90%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.31 - $0.09
    5 analysts
    EPS Revisions
    2
    0
    7d
    1
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.17+8.5%
    60d ago$-0.17+8.5%
    30d ago$-0.17+8.5%
    7d ago$-0.16+4.8%
    Current$-0.15
    Revenue Consensus
    $27M
    Range$25M - $29M
    10 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.21
    Range$0.04 - $0.33
    5 analysts
    Revenue Consensus
    $58M
    Range$33M - $64M
    10 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.21---
    Sep 26EST
    		-$-0.15---
    Jun 26
    Reported Aug 5
    		$-0.29$-0.37+21.62%Beat+0.0%
    Mar 26
    Reported May 6
    		$-0.19$-0.15-26.67%Miss-533.3%
    Dec 25
    Reported Feb 25
    		$-0.03N/A+91.12%Beat-200.0%
    Sep 25
    Reported Nov 5
    		$-0.24$-0.34+29.41%Beat-50.0%
    Jun 25
    Reported Aug 7
    		$-0.29$-0.28-3.57%Miss-81.2%
    Mar 25
    Reported May 7
    		$-0.03N/A+62.50%Beat+75.0%
    Dec 24
    Reported Feb 25
    		$0.03N/A+117.65%Beat+111.5%
    Sep 24
    Reported Nov 7
    		$-0.16$-0.07-128.57%Miss+15.8%
    Jun 24
    Reported Aug 5
    		$-0.16$-0.11-45.45%Miss+42.9%
    Mar 24
    Reported May 6
    		$-0.12$-0.19+36.84%Beat+61.3%
    Dec 23
    Reported Feb 28
    		$-0.26$-0.36+27.78%Beat+53.6%
    Sep 23
    Reported Nov 9
    		$-0.19$-0.35+45.71%Beat+68.9%
    Jun 23
    Reported Aug 7
    		$-0.28$-0.39+28.21%Beat+54.1%
    Mar 23
    Reported May 9
    		$-0.31$-0.45+31.11%Beat+51.6%
    Dec 22
    Reported Mar 6
    		$-0.56$-0.75+25.33%Beat+3.4%
    Sep 22
    Reported Nov 7
    		$-0.61$-0.68+10.29%Beat+10.3%
    Jun 22
    Reported Aug 8
    		$-0.61$-0.65+6.15%Beat-19.6%
    Mar 22
    Reported May 5
    		$-0.64$-0.60-6.67%Miss-77.8%
    Dec 21
    Reported Mar 8
    		$-0.58$-0.68+14.71%Beat+65.9%
    Sep 21
    Reported Nov 10
    		$-0.68$-0.62-9.68%Miss-
    Jun 21
    Reported Jul 30
    		$-0.51$-0.70+27.14%Beat-
    Mar 21
    Reported Jun 2
    		$-0.36$0.00N/AMiss-
    Dec 20
    Reported Mar 31
    		$-1.70$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-6.04EV/EBITDAN/A
    Price/FCF-6.92xFCF Yield-14.45%
    Profitability
    Profit Margin-36.80%Operating Margin-40.80%
    ROE-17.30%ROIC-20.24%
    Financial Health
    Debt/Equity0.03xInterest Coverage-3936.64x
    Current Ratio4.07xQuick Ratio3.61x
    Trading Statistics
    Beta1.14Avg Volume782.62K
    52-Week High$13.2252-Week Low$4.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.74
    SMA 20$4.85
    SMA 50$5.83
    SMA 200$6.71
    EMA 10$4.75
    EMA 20$4.98
    EMA 50$5.43
    EMA 200$6.77

    MACD

    Line: -0.32Signal: -0.35Hist: 0.03

    ADX

    ADX: 25.4+DI: 15.8-DI: 27.6

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down100.0
    PSAR$4.98

    Bollinger Bands

    Upper Band$5.32
    Lower Band$4.38
    %B Position1945%(Upper)
    Band Width0.16

    RSI (14-Day)

    Neutral
    31.8

    Momentum Oscillators

    Stoch %K26.0
    Stoch %D30.2
    Williams %R-84.4
    ROC (10d)-5.0%
    Momentum-0.24
    CCI (20d)-103.6
    MFI (14d)39.7

    Volatility Measures

    ATR (14d)$0.28(6.1%)
    StdDev (20d)0.24
    Hist Vol34.8%(Moderate)

    Volume Flow

    VWAP$4.58
    OBV-21.3M
    AD Line9.3M
    CMF (20d)-0.239

    Volume Metrics

    Avg Vol (20d)795.3K
    Vol Ratio0.9x
    VWMA (20d)$4.86

    Pivot Points

    R3$5.34
    R2$5.16
    R1$4.91
    Pivot Point$4.73
    S1$4.48
    S2$4.30
    S3$4.05

    Advanced Oscillators

    TSI-33.31
    Ultimate Osc43.2
    KST-222.08

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$33.74M$30.89M$32.61M$30.34M$33.64M$37.90M$40.21M$35.31M$34.89M$29.51M$28.58M$22.20M
    Cost of Revenue$0$7.39M$7.34M$6.11M$0$9.57M$11.43M$10.09M$10.64M$8.83M$10.93M$8.47M
    Gross Profit$33.74M$23.50M$25.26M$24.23M$33.64M$28.33M$28.79M$25.22M$24.25M$20.68M$17.65M$13.73M
    Operating Expenses$47.51M$41.33M$36.60M$36.41M$47.64M$39.00M$37.42M$34.45M$32.58M$31.36M$28.50M$26.24M
    R&D$9.24M$9.47M$8.90M$9.06M$10.22M$10.37M$9.21M$8.84M$8.29M$8.03M$7.34M$7.10M
    SG&A$30.42M$31.86M$27.69M$27.34M$28.98M$28.64M$28.21M$25.61M$24.29M$23.32M$21.16M$19.14M
    Operating Income$-13,770,000$-17,829,000$-11,336,000$-12,178,000$-14,003,000$-10,674,000$-8,629,000$-9,226,000$-8,333,000$-10,670,000$-10,851,000$-12,512,000
    Interest Income$1.76M$1.95M$2.19M$2.38M$2.25M$2.51M$2.71M$2.91M$2.28M$1.58M$1.66M$1.75M
    Interest Expense$3,000$3,000$4,000$4,000$5,000$6,000$4,000$5,000$6,000$6,000$3,000$1.64M
    Income Before Tax$-12,009,000$-15,878,000$-9,146,000$-9,806,000$-11,754,000$-8,172,000$-5,926,000$-6,325,000$-6,063,000$-9,091,000$-9,195,000$-12,403,000
    Income Tax Expense$88,000$6,000$6,000$10,000$32,000$18,000$12,000$13,000$16,000$9,000$-18,000$12,000
    Net Income$-12,097,000$-15,884,000$-9,152,000$-9,816,000$-11,786,000$-8,190,000$-5,938,000$-6,338,000$-6,079,000$-9,100,000$-9,177,000$-12,415,000
    EBITDA$-14,523,000$-18,849,000$-12,317,000$-13,468,000$-15,357,000$-12,300,000$-10,783,000$-10,856,000$-9,586,000$-11,035,000$-11,509,000$-12,970,000
    EBIT$-13,770,000$-17,829,000$-11,336,000$-12,178,000$-14,003,000$-10,674,000$-8,629,000$-9,226,000$-8,333,000$-10,670,000$-10,851,000$-12,512,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RXST

    News

    RxSight announces Alcon lens deal as analysts target RxSight stock at USD 8.17

    RxSight has announced a non-exclusive collaboration with Alcon for up to $200 million to develop adjustable presbyopia-correcting intraocular lenses. This deal allows RxSight to expand beyond cataract surgery...

    ad-hoc-news.de•10/15/26•Neutral

    Watkins Advises RxSight on Collaboration With Alcon to Develop Adjustable PCIOLs

    Latham & Watkins LLP advised RxSight in a non-exclusive collaboration with Alcon to co-develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership aims to combine RxSight's light-adjustable...

    Latham & Watkins LLP•10/15/26•Bullish

    Jefferies cuts target for RxSight stock to USD 5.75

    Jefferies has reduced its target for RxSight (RXST) stock to USD 5.75 from USD 6.50, maintaining a Hold rating. This adjustment follows RxSight's Q2 2026 revenue of USD 33.74 million, which exceeded consensus...

    AD HOC NEWS•10/5/26•Somewhat-Bearish

    Is the New Setup at RxSight (NASDAQ:RXST) Sustainable?

    RxSight (NASDAQ:RXST) is currently under scrutiny due to tight financial conditions emphasizing the importance of funding runway and company-specific demand. The article questions whether the company's focus...

    Kalkine Media•10/1/26•Neutral

    RxSight stock faces a lower Jefferies target at USD 5.75

    RxSight, Inc. (RXST) reported a Q2 2026 adjusted loss of USD 0.29 per share, outperforming the consensus of USD 0.33, with revenues of USD 33.74 million. Despite the revenue beat and better-than-expected loss...

    AD HOC NEWS•10/1/26•Somewhat-Bearish

    RXST Valuation and Fair Value

    P/E
    -6.0x
    Forward P/E
    116.3x
    P/FCF
    -6.9x
    P/B
    0.7x
    See GNG's fair value

    RXST Profitability: Margins, ROIC and FCF

    Gross margin
    83.7%
    Operating margin
    -40.8%
    Net margin
    -36.8%
    ROIC
    -20.2%
    ROE
    -17.3%
    FCF margin
    -21.3%
    FCF yield
    -14.5%

    RXST Competitors

    CompanyTicker
    Entrada Therapeutics IncTRDA
    Upstream Bio, Inc.UPB
    Eledon Pharmaceuticals IncELDN
    Sharps Technology IncSTSS
    Akebia TherAKBA
    Sionna Therapeutics, Inc. Common StockSION
    Niagen Bioscience, Inc.NAGE
    Invivyd Inc.IVVD

    Sector: Healthcare

    RXST Analyst Ratings

    Consensus
    Hold
    Analysts
    10
    Strong Buy
    1
    Buy
    0
    Hold
    7
    Sell
    0
    Strong Sell
    2

    RXST Bull Case vs Bear Case

    Bear case

    • RXST has a -36.8% net profit margin.

    RXST Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    20.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.15
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 3 down

    Frequently Asked Questions About RXST

    Does RXST pay dividends?

    Rxsight Inc (RXST) does not currently pay a regular dividend.

    What is RXST's market cap?

    Rxsight Inc (RXST) has a market capitalization of $188.00M with a current stock price of $4.53.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In